U.S. Neurology Clinical Trials Market (2025 - 2033)

U.S. Neurology Clinical Trials Market Summary

The U.S. neurology clinical trials market size was estimated at USD 2.53 billion in 2024 and is projected to reach USD 4.47 billion by 2033, growing at a CAGR of 6.59% from 2025 to 2033. The growth of the U.S. market for neurology clinical trials is driven by significant advancements in neuroscience, increasing healthcare spending, and an emphasis on targeted therapies for intricate neurological conditions.

Other factors driving the growth of the U.S. neurology clinical trials industry include increasing patient awareness, regulatory support for orphan drugs and breakthrough therapies, and rising investment in neurology research and development. The rising incidence of neurodegenerative diseases, supported by a well-established clinical research infrastructure, has established the U.S. as a key center for neurology trials. Furthermore, funding from both public and private sectors and strategic partnerships among pharmaceutical companies, contract research organizations (CROs), and academic institutions have played a crucial role in speeding up study timelines and enhancing trial efficiency, further supporting the market.

The increasing prevalence of Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and various rare neurological syndromes has created an increased need for novel treatment options, resulting in a rise in the number of clinical trial activities. These studies are conducted in early and late stages, with more advanced programs concentrating on disease-modifying therapies, neuroprotective agents, and gene-based interventions. In addition, pharmaceutical and biotechnology companies are expanding in-house CRO capabilities to maintain control over study protocols, enhance execution speed, and increase operational efficiency for clinical trials. Besides, a growing number of investigator sites specializing in neurology are further improving patient recruitment accuracy, optimizing trial quality, and shortening enrollment timelines. This blend of in-house capabilities and specialized site expertise boosts the scale and rate of neurological trial delivery across the country.

Moreover, market trends are shifting towards adopting decentralized and hybrid trial models, allowing for broader patient participation and faster data collection. Further, the growing incorporation of advanced neuroimaging techniques, biomarker-based diagnostics, and AI-driven patient selection tools is enhancing the precision of trials and the predictability of outcomes. Furthermore, numerous biopharmaceutical companies are expanding their neurology research portfolios and site networks to strengthen their geographic reach, accelerate regulatory approvals, and better address the unmet needs of patients in underserved areas, further supporting the U.S. neurology clinical trials market.

Thus, the neurology clinical trials market is crucial to the U.S. healthcare industry, as it tackles conditions that heavily influence healthcare costs, workforce productivity, and patients' overall quality of life. Besides, these trials are essential for converting scientific innovations into market-ready treatments while reducing disease burden. Such aforementioned factors are expected to drive the market over the estimated timeframe.

Opportunity Analysis

The U.S. neurology clinical trials market presents significant growth opportunities driven by the rising prevalence of neurodegenerative and rare neurological disorders, coupled with an aging population. Besides, increasing demand for disease-modifying therapies, gene-based treatments, and precision medicine fuels the market innovation across early and late-phase trials. In addition, expanding adoption of decentralized trial models, AI-driven patient recruitment, and advanced neuroimaging is improving efficiency, reducing costs, and broadening patient access.

Moreover, strategic collaborations among pharmaceutical companies, CROs, academic institutions, and investigator sites with specialized expertise are accelerating drug development timelines, further offering several new growth opportunities. Further, strong regulatory support, orphan drug incentives, and robust public-private funding are enhancing the market’s growth. With a growing pipeline of monoclonal antibodies, neuroprotective agents, and novel diagnostics, the U.S. is anticipated to maintain its market position in global neuroscience research, offering significant opportunities for stakeholders to capitalize on evolving therapeutic innovations, invest in clinical trials, and address unmet patient needs in the neurological market.

Impact of U.S. Tariffs on the Neurology Clinical Trials Market

The U.S. neurology clinical trials industry has experienced significant disruptions due to tariffs and trade tensions, affecting the supply chain for vital trial materials and equipment. The costs of key imported components such as specialized diagnostic devices, imaging systems, laboratory reagents, and high-tech monitoring tools have seen increased costs, leading to delayed deliveries. These issues have resulted in slower patient enrollment, postponed study initiations, and interruptions in ongoing trials, especially for early-phase neurology studies that rely on imported instruments and biomarker assays. Besides, smaller CROs and investigator sites have been affected particularly by rising costs and procurement delays, hindering operational flexibility and trial execution efficiency.

Despite these challenges, the U.S. neurology clinical trials market will likely maintain steady growth due to strong domestic capabilities, robust funding, and high demand for innovative neurological therapies. Besides, market expansion is driven by increased prevalence of neurodegenerative disorders, adoption of decentralized trial models, and technology integration, including AI-driven recruitment and remote monitoring. Regulatory incentives, collaborative partnerships between pharmaceutical companies and CROs, and strategic portfolio diversification have strengthened resilience. While tariffs introduced short-term cost pressures and supply chain uncertainties, ongoing investments in local sourcing, strategic alliances, and advanced trial infrastructure continue to support the long-term growth of neurology clinical trials in the U.S.

Technological Advancements

The U.S. market for neurology clinical trials has witnessed the rise of new innovative technologies that enhance efficiency, accuracy, and patient outcomes. Techniques like high-resolution MRI, PET, and functional imaging allow for precise disease detection, monitoring, and treatment evaluation, all supported by AI-powered image analysis for deeper insights. In addition, AI-driven patient recruitment and selection approaches utilize extensive healthcare datasets and predictive algorithms to quickly identify eligible participants, thus improving diversity and shortening recruitment timelines.

Besides, wearable and remote monitoring devices such as EEG headbands and motion sensors enable continuous real-world symptom tracking, supporting decentralized trials and improving participant adherence. Biomarker-based diagnostics, which draw on genetic, proteomic, and metabolomic data, facilitate early disease identification and enable targeted trial designs, increasing success rates via precision medicine strategies. Moreover, digital clinical trial platforms integrate data from diverse sources, offering real-time analytics, ensuring regulatory compliance, and streamlining stakeholder collaboration. Thus, these innovations are reducing trial costs, speeding up drug development timelines, and enhancing the chances of regulatory approval for new neurology therapies in the U.S. market.

The U.S. neurology clinical trials industry employs diverse pricing models to align sponsor goals with operational efficiency and financial predictability. Milestone-based pricing ties payments to the completion of specific trial phases or objectives, such as patient enrollment or data lock, incentivizing timely achievement of deliverables and reducing financial risk for sponsors. Fixed-fee models establish a predetermined cost for the defined scope, offering predictable budgeting and encouraging operational efficiency, though flexibility is limited for unforeseen changes. Value-based pricing links fees to trial outcomes or therapeutic impact, particularly for breakthrough therapies or orphan indications, aligning incentives between sponsors and CROs while fostering innovation in trial design. The subscription or retainer model involves recurring payments for continuous access to CRO services, infrastructure, and expertise, supporting long-term collaborations, rapid trial initiation, and adaptive study designs. Thus, these models enable cost management, strategic partnership, and efficient execution of complex neurology trials in the U.S. market.

Market Concentration & Characteristics

The U.S. neurology clinical trials market growth stage is moderate, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.

The U.S. neurology clinical trials market demonstrates high innovation, driven by advanced therapies including gene editing, monoclonal antibodies, neuroprotective agents, and precision medicine approaches. Novel study designs, biomarkers, and AI-based tools accelerate development and improve trial efficiency.

Regulatory frameworks, including FDA guidance on orphan drugs, breakthrough therapy designations, and adaptive trial protocols, strongly influence U.S. neurology clinical trials. Compliance ensures patient safety, accelerates approvals, and drives investment in innovative therapies.

Mergers and acquisitions are moderately active in the U.S. neurology trials sector. CROs, biotech, and pharmaceutical companies are consolidating capabilities to expand portfolios, integrate specialized expertise, and enhance operational scale for innovative neurological therapies.

Service expansion in neurology trials includes decentralized study models, advanced patient recruitment, remote monitoring, biomarker analysis, and integrated data management, enabling CROs and sponsors to offer end-to-end trial solutions and improve operational efficiency.

Regional expansion focuses on extending trial sites across underserved areas, increasing access to diverse patient populations, and enhancing recruitment efficiency. This strategy supports broader data collection, faster enrollment, and representation across multiple U.S. states for neurology studies.

Phase Insights

In 2024, the phase III segment held the largest share of the U.S. neurology clinical trials industry, accounting for a revenue share of 40.79%. Phase III neurology clinical trials in the U.S. represent the major stage for evaluating the safety & efficacy of novel therapies on larger patient populations. These highly resource-intensive trials involve multi-center recruitment, extensive data collection, and regulatory oversight. Besides, the increasing prevalence of neurodegenerative disorders, rising investment in disease-modifying therapies, and advanced trial technologies further support the market growth. In addition, a growing number of CRO partnerships and in-house trial capabilities are leveraged to optimize study execution, reduce timelines, and ensure compliance with FDA requirements, enabling smoother transitions toward commercialization. Such factors are expected to drive the market over the estimated time period.

The phase I segment is expected to grow significantly during the forecast period. Phase I neurology clinical trials focus on the first-in-human evaluation of investigational therapies, which primarily assess safety, tolerability, and pharmacokinetics. Besides, increased innovation in gene therapies, monoclonal antibodies, and neuroprotective agents supports the growth. Early engagement of CROs and academic institutions allows for rapid patient recruitment and protocol optimization, further supporting market growth. In addition, advanced biomarkers and imaging technologies enhance data precision, while regulatory incentives for orphan and breakthrough therapies encourage investments in the market. These trials form the foundation for subsequent efficacy studies, positioning the U.S. as a global leader in early-phase neurology research. For instance, in February 2024, Aruna Bio mentioned the Phase I/II clinical trial initiation for AB126, an allogeneic neural exosome derived from neural stem cells. These clinical trials collaborate with the Regenerative Bioscience Center at the University of Georgia. The study will assess the safety, tolerability, and preliminary efficacy of the therapy in ischemic stroke patients who have a poor prognosis following thrombectomy. Such strategic initiatives are expected to drive the market over the estimated time period.

Study Design Insights

In 2024, the interventional studies segment accounted for the largest revenue share in the U.S. neurology clinical trials market. The segment growth is expanding due to growing demand for disease-modifying treatments in Alzheimer’s, Parkinson’s, multiple sclerosis, and rare neurological disorders. These interventional neurology clinical trials in the U.S. widely involve actively administering investigational drugs, devices, or procedures to evaluate therapeutic impact. Besides, advanced trial design, digital monitoring tools, and AI-driven patient selection are expected to support the market for improved efficiency and outcomes. Also, CROs and in-house teams play a pivotal role in protocol implementation, compliance, and site management. In addition, strategic partnerships & funding support the acceleration of innovation, enabling faster progression of promising therapies toward regulatory approval & commercialization.

The observational segment is expected to witness the second-fastest CAGR during the forecast period. The segment’s growth is driven by the rising prevalence of neurodegenerative disorders and regulatory emphasis on patient-centric evidence. Integration of wearable devices, digital health platforms, and electronic health records enables continuous data collection and analysis. In addition, observational neurology clinical trials support monitoring patient populations without intervention, collecting real-world data to understand disease progression, history, and treatment outcomes. Besides, these studies complement interventional trials by providing insights into long-term outcomes, biomarker validation, and population diversity, further supporting the market. Also, growing investments in real-world evidence and collaboration between CROs, academic institutions, and sponsors are expected to drive the market.

Indication Insights

The Alzheimer’s disease segment accounted for the largest share of the U.S. neurology clinical trials industry in 2024. This can be attributed to the increasing prevalence of Alzheimer’s disease, an aging population, and rising public-private investments focused on both disease-modifying and symptomatic therapies. Besides, the growing emphasis on early-stage detection that utilizes biomarkers, neuroimaging, and genetic profiling to enhance patient stratification further supports the market. Despite facing challenges like high trial failure rates, lengthy timelines, and recruitment hurdles, innovations in adaptive trial designs, decentralized approaches, and digital cognitive assessments are improving the efficiency of clinical trials in the U.S. Besides, prominent sponsors such as Biogen, Eli Lilly, and Alzheon are focusing on progress with their late-phase candidates. In addition, the support from federal funding, regulatory incentives, and specialized clinical networks solidifies the U.S. as a crucial hub for advancements in Alzheimer's research.

The Huntington's disease segment is expected to grow at the fastest CAGR during the forecast period. Advancements in genetic therapies, biomarker research, and patient-focused trial designs drive growth of the U.S. Huntington's disease clinical trials market. Besides, the indication has no curative treatments available, leading to increased focus on research activities prioritizing the disease-modifying interventions, including gene silencing, antisense oligonucleotides, and stem cell approaches. In addition, the recruitment for this indication remains challenging due to the disease's shortage; however, patient registries and advocacy networks are improving enrollment efficiency. Moreover, regulatory support, orphaned drug incentives, and collaborations among biopharma companies & academic centers are expected to accelerate progress and support the market growth. Key sponsors for this indication include uniQure, Voyager Therapeutics, and Roche/Genentech, which are advancing novel candidates. Such factors are expected to leverage the specialized neurology trial sites and advanced imaging technologies.

Value Chain Insights

The in-house segment held the largest share of the U.S. neurology clinical trials market in 2024. In-house neurology clinical trials support the pharmaceutical and biotech companies' capabilities for protocol design, patient recruitment, and data management without outsourcing to CROs. The segment benefits from strong research infrastructure, specialized neurology expertise, and integrated technological platforms. Besides, in-house trials allow for stringent control over study quality, timelines, and regulatory compliance, enabling faster iterations and adaptive designs. Also, collaboration with investigator sites and academic institutions enhances patient access, further supporting the market. In addition, companies are increasingly combining in-house operations with technology adoption, including AI, biomarkers, and digital monitoring, to optimize efficiency and maintain a competitive advantage in neurology drug development, which is anticipated to drive the market over the estimated timeframe.

The contract research organizations (CROs) segment is expected to witness the fastest CAGR over the forecast period. CROs play a central role in the U.S. neurology clinical trials market by providing specialized services, including site management, patient recruitment, data analytics, and regulatory support. Besides, the growing complexity of trials, particularly for Alzheimer's, Parkinson's, and rare disorders, has increased reliance on CRO expertise. In addition, advanced technologies such as AI-driven recruitment, digital monitoring, and biomarker analysis are integrated to improve efficiency. Strategic partnerships between sponsors and CROs facilitate scalable multi-center trials with accelerated timelines. This model enables cost-effective execution, supports innovation, and strengthens the U.S.'s position as a global neurology research market.

Key U.S. Neurology Clinical Trials Company Insights

The key market players are adopting inorganic strategic initiatives such as partnerships, mergers, acquisitions, service launches, partnerships & agreements, and expansions to gain a competitive edge. For instance, in June 2025,QSCTC mentioned that it is progressing a pipeline of clinical trials in 2025, with plans to broaden support for all late-phase studies across Queen Square. The center complements the NIHR UCLH LWENC Clinical Research Facility, which specializes in early-phase trials. Backed by the UCL Queen Square Institute of Neurology, BRC Translational Neuroscience theme, and UCLH National Hospital for Neurology and Neurosurgery, QSCTC collaborates closely with LWENC-CRF, the Research Directorate/JRO, and the Dementia Research Centre to ensure integrated trial delivery and translational research support.

Recent Developments

• In June 2025, Neuro mentioned that it is advancing its clinical research in rare genetic disorders with a pioneering study of the first potential RNA-based therapy for Spinocerebellar Ataxia Type 2 (SCA2), a group of inherited neurological conditions. The treatment targets and inhibits the defective ataxin-2 gene in the brain and spinal cord, to close or potentially reverse disease progression. Moreover, until now, no effective treatments exist for SCA2, a life-threatening disorder that occurs with higher prevalence in Quebec.

• In September 2024, Abbott mentioned the introduction of a new clinical trial called the TRANSCEND study, which aims to evaluate the effectiveness of its innovative deep brain stimulation (DBS) device in treating hard-to-manage depression. This type of major depressive disorder (MDD) is particularly challenging, as it does not respond to at least two previous treatment attempts. In addition, the program is likely to speed up regulatory evaluation of new technologies aimed at enhancing the quality of life for individuals with life-threatening or permanently disabling diseases or conditions.

U.S. Neurology Clinical Trials Market